Multiple Sclerosis, Relapsing Remitting Clinical Trial
Official title:
An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings
The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of this improved formulation (with regards to adverse events [AEs]) to subjects' adherence.
This international, multicentric, prospective, observational study is being conducted to
assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life
settings in subjects with relapsing remitting multiple sclerosis (RRMS), as well as the
impact of this improved formulation (with regards to adverse events [AEs]) to subjects'
adherence. Three hundred and fifty subjects from approximately 80 sites across seven
countries will be enrolled in the study. Subjects will be treated with IFN beta-1a (Rebif®
New Formulation) in real life settings according to the clinical and paraclinical course and
laboratory findings as routinely evaluated by the physician. Data related to AEs; subjects'
adherence to treatment, reasons for treatment discontinuation; number and reasons of missed
injections; and the clinical and paraclinical data on efficacy regarding relapses will be
captured. Data will be reported prospectively throughout the duration of the study (12
months) at two visits (at month 6 and month 12) following the initial visit; at baseline,
data can be recorded retrospectively from the subjects' medical file. All the data will be
evaluated descriptively.
OBJECTIVES
Primary objective
- To assess the local tolerability of Rebif® New Formulation in real life settings with a
multinational approach.
Secondary objectives
- To assess the safety profile, subjects' adherence to and efficacy of Rebif® New
Formulation
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02247310 -
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
|
N/A | |
| Completed |
NCT01080053 -
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
|
N/A | |
| Completed |
NCT00859482 -
Differential Immune Effects of Natalizumab
|
N/A | |
| Completed |
NCT02638038 -
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
|
Phase 2 | |
| Completed |
NCT01080040 -
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
|
N/A |